Citigroup
PHAT icon

Citigroup’s Phathom Pharmaceuticals PHAT Stock Holding History

Citigroup’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574K Buy
52,945
+23,576
+80% +$269K ﹤0.01% 3824
2026
Q1 		$326K Buy
29,369
+910
+3% +$11.5K ﹤0.01% 3768
2025
Q4 		$472K Buy
28,459
+14,824
+109% +$212K ﹤0.01% 3602
2025
Q3 		$160K Sell
13,635
-503,612
-97% -$5.2M ﹤0.01% 4082
2025
Q2 		$4.96M Sell
517,247
-13,612
-3% -$75.3K ﹤0.01% 1897
2025
Q1 		$3.33M Buy
530,859
+486,282
+1,091% +$2.95M ﹤0.01% 2268
2024
Q4 		$362K Buy
44,577
+13,056
+41% +$162K ﹤0.01% 4043
2024
Q3 		$570K Buy
31,521
+22,665
+256% +$317K ﹤0.01% 3648
2024
Q2 		$91.2K Buy
8,856
+2,811
+47% +$29K ﹤0.01% 4257
2024
Q1 		$64.2K Buy
6,045
+396
+7% +$3.36K ﹤0.01% 4504
2023
Q4 		$51.6K Buy
5,649
+1,821
+48% +$15.7K ﹤0.01% 4499
2023
Q3 		$39.7K Sell
3,828
-5,256
-58% -$72.1K ﹤0.01% 4208
2023
Q2 		$130K Buy
9,084
+8,138
+860% +$93.8K ﹤0.01% 4108
2023
Q1 		$6.75K Sell
946
-186
-16% -$1.63K ﹤0.01% 4868
2022
Q4 		$12.7K Sell
1,132
-115
-9% -$1.19K ﹤0.01% 4767
2022
Q3 		$14K Sell
1,247
-1,262
-50% -$12K ﹤0.01% 4885
2022
Q2 		$21K Buy
2,509
+413
+20% +$4.25K ﹤0.01% 4977
2022
Q1 		$29K Sell
2,096
-5,355
-72% -$86.5K ﹤0.01% 4969
2021
Q4 		$147K Buy
7,451
+1,971
+36% +$46.4K ﹤0.01% 4532
2021
Q3 		$176K Buy
5,480
+2,640
+93% +$87.7K ﹤0.01% 4181
2021
Q2 		$96K Buy
2,840
+993
+54% +$35.6K ﹤0.01% 4528
2021
Q1 		$69K Sell
1,847
-1,447
-44% -$60.5K ﹤0.01% 4536
2020
Q4 		$110K Buy
3,294
+2,176
+195% +$88.2K ﹤0.01% 5469
2020
Q3 		$41K Sell
1,118
-2,144
-66% -$74.3K ﹤0.01% 5726
2020
Q2 		$107K Buy
3,262
+21
+0.6% +$807 ﹤0.01% 5520
2020
Q1 		$83K Buy
3,241
+1,083
+50% +$36.2K ﹤0.01% 5509
2019
Q4 		$67K Buy
+2,158
New +$54.2K ﹤0.01% 6092

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Citigroup's PHAT Position: Q2 2026 in Review

Citigroup increased its Phathom Pharmaceuticals (PHAT) stake by 80% in Q2 2026, buying an estimated $269K and bringing the position to 52,945 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

Citigroup first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.96M in Q2 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Citigroup held 52,945 shares of Phathom Pharmaceuticals worth $574K as of Q2 2026.
  • Citigroup bought 23,576 Phathom Pharmaceuticals shares in Q2 2026, an estimated $269K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3824 holding.
  • Citigroup first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Citigroup's Phathom Pharmaceuticals position peaked at $4.96M in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.